Stocks · News reference

Truist Securities Maintains Buy on MannKind, Lowers Price Target to $5

Oct 7, 2026, 4:51 PMBenzinga Newsdesk

Truist Securities analyst Gregory Renza maintains MannKind (NASDAQ:MNKD) with a Buy and lowers the price target from $6 to $5.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

Globenewswire IncOct 14, 2026, 8:01 PMNa
MannKind to Participate in the Chardan Healthcare Conference
MannKind Corporation announced that CEO Michael Castagna will participate in a panel discussion on innovation in chronic respiratory diseases at the Chardan Healthcare Conference on October 20, 2026. The company will also conduct one-on-one investor meetings. MannKind is a biopharmaceutical company focused on cardiometabolic and orphan lung diseases, with treatments addressing diabetes, pulmonary hypertension, and fluid overload conditions.
MNKD
BenzingaOct 12, 2026, 8:18 AMBenzinga Newsdesk
Reported Friday, MannKind’s Under-10-Second Furoscix ReadyFlow Autoinjector Shows Urine Output Comparable To IV Furosemide In New HFSA 2026 Analyses, Supporting Outpatient Edema Management In Heart Failure And CKD
New analyses on Furoscix ReadyFlow PK/PD performance delivered via an autoinjector demonstrated comparable urine output to IV furosemideConsistent bioavailability, diuresis and natriuresis across injection sites support
MNKD
BenzingaSep 11, 2026, 11:07 AMBenzinga Newsdesk
Cantor Fitzgerald Reiterates Overweight on MannKind, Maintains $8 Price Target
Cantor Fitzgerald analyst Olivia Brayer Saunders reiterates MannKind (NASDAQ:MNKD) with a Overweight and maintains $8 price target.
MNKD